Navigation Links
Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies
Date:11/29/2007

r other tissues.

Applications of these two approaches include treating the effects of neurological diseases such as Down syndrome, Alzheimer's and Parkinson's; healing damaged heart tissue after heart attacks; increasing bone and muscle strength in the severely frail; and protecting organs after infection or transplantation. Fate will also tackle devastating cancers, such as pancreatic and colorectal cancer, by developing drugs to prevent the expansion and maturation of cancer stem cells.

Fate's approach differs significantly from others working with stem cells

To date, most stem cell companies have focused on cell therapy using harvested cells from cord blood or other tissues. In contrast, Fate's approach focuses exclusively on traditional therapeutics, namely small molecules and protein therapeutics, to direct cell fate. In addition to its novel approach, Fate's work has potential broad application across all degenerative diseases, developmental disorders and cancers, and in enabling the creation of healthy patient-identical cells for transplantation.

"We have looked at investing in many stem cell companies, but the science and commercial reality just wasn't there yet," said Robert Nelsen, founding partner of ARCH Venture Partners, whose firm co-founded Fate. "Now is the perfect storm; the right biology breakthroughs; a targeted way to use real drugs; and the leading scientists, entrepreneurs, and investors -- all in the same company to develop breakthrough medicines."

Founders' breakthroughs are breathtaking in scope and implication

Fate's founders include researchers from across the United States and multiple scientific disciplines, including basic biology, biological chemistry and translational medicine. As authors of many of the most far-ranging breakthroughs in stem cell science, the team is defining the changes in the field:

-- Philip Beachy, Ph.D., Stanford University Institute for Stem Cell

B
'/>"/>

SOURCE Fate Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... , Sept. 29, 2014 /PRNewswire/ - Portage Biotech Inc. ... PBT.U), is pleased to announce that its three Promissory ... Portage, who advanced $ 100,000 each in July 2014 ... their Notes and related Coupons converted into 3,500,001 restricted ... carried 5% coupon. Both the Note and the coupon ...
(Date:9/29/2014)... , Sept. 29, 2014 Research ... "Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph Market ... & Region - Global Trends & Forecast to 2013 ... A process analyzer is a process analytical instrument ... real-time. It has redefined the way by which companies ...
(Date:9/29/2014)... ACEA Biosciences, Inc. (ACEA) has ... iCELLigence Research Grant for his proposal on cancer ... an impedance based real-time label-free cellular analysis instrument. ... Biomedical Engineering at Yale University currently holds a ... Professor Rong Fan's laboratory involve the ...
(Date:9/29/2014)... - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: SQIDF), a ... and products for advanced microarray diagnostics, is pleased to ... Chairman of the Board of Directors of SQI, replacing ... serve as a Director on the Board and will ... "We are very pleased to have Mr. Winkley ...
Breaking Biology Technology:Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 2Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 4ACEA Biosciences, Inc. Awards Yale University Researcher the iCELLigence Research Grant 2SQI Diagnostics Announces New Chairman of Board of Directors 2
... /Xinhua-PRNewswire-FirstCall/ --,China Biologic Products, Inc. (OTC Bulletin ... of the leading plasma-based pharmaceutical companies,in the ... that the Company,received approval from the PRC ... commence clinical trial of its new Human ...
... Cytotoxic ... Compound Market, ... development organization supporting the,pharmaceutical industry -- today announced the opening ... The 18,000 sq. ft. facility includes newly constructed analytical and,formulation ...
... (Nasdaq: SGMO ) announced today that Edward Lanphier,Sangamo,s ... progress of,Sangamo,s ZFP Therapeutic development programs and an overview ... Tuesday, September 23,2008, at the 2008 UBS Global Life ... will be webcast live and may be accessed via ...
Cached Biology Technology:China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII 2China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII 3Pharmatek Announces Official Opening of New Highly-Potent & Cytotoxic Development and Manufacturing Facility 2Sangamo BioSciences to Present at the UBS Global Life Sciences Conference 2
(Date:9/29/2014)... . Montreal, ... expectant mother was deprived of electricity during Quebec,s Ice ... a new study finds., Scientists from the Douglas Mental ... distinctive ,signature, in the DNA of children born in ... months after the event, researchers recruited women who had ...
(Date:9/29/2014)... Sclerosis (MS) were able to safely tolerate treatment with ... study published today in the journal Multiple Sclerosis ... first of its kind, was conducted by researchers at ... and collaborators at several other institutions. , While ... in the data also suggested that a preparation of ...
(Date:9/27/2014)... The first direct comparison of treating non-squamous lung ... to cisplatin has shown that the two combinations ... with more frequent adverse events. , At the ... from Chonnam National University Medical School, South Korea, ... trial that included 149 patients with non-squamous non-small ...
Breaking Biology News(10 mins):Cells from placentas safe for patients with multiple sclerosis 2Docetaxel or pemetrexed with cisplatin achieve comparable outcomes in non-squamous Lu Ca 2
... molecule made by the human body that triggers the immune ... to new research published today in Nature Medicine . ... that if scientists could block this signal, it may be ... is the most common autoimmune disease, affecting around 1 in ...
... canopies bear little resemblance to their seedlings, many described ... "Seedlings of Barro Colorado Island and the Neotropics," published ... Garwood, professor of plant biology at the University of ... describing seedling stages of tropical plants 25 years ago ...
... Lieberman (I-CT) and John Cornyn (R-TX) today introduced the ... ensure free, timely, online access to the published results ... proposed bill is welcomed by the Alliance for Taxpayer ... others formed to support open public access to publicly ...
Cached Biology News:New trigger for chronic inflammation in rheumatoid arthritis discovered 2New guide to tropical seedlings: Essential to climate change research 2Taxpayer Alliance applauds bill to broaden access to federal research results 2
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... This CLS number is ... created to easily match ... showing no availability yet, ... old Sigma-Aldrich number (Z71,381-3) ...
...
... Gel loading buffer is especially formulated for ... nucleic acids. The gel loading solution contains ... to add density and facilitate sample loading. ... that require divalent cations and SDS has ...
Biology Products: